image credit- freepik
US-based NJ Bio, Inc., a leading provider of integrated drug discovery and development services and Japan's Ajinomoto Bio‑Pharma Services, a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients.
This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody–drug conjugates (ADCs) and other targeted therapeutics.
Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.
AJICAP™ technology is widely recognised for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end‑to‑end support, from early drug design and discovery through preclinical development.
